Mirum PharmaceuticalsMIRM
Recorded

Mirum Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration20 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Peter RadovichPresident and COO

Hi, everyone. I'm Peter Radovich, President, Chief Operating Officer at Mirum, and I just want to thank you all in advance for taking time out of your conference schedule to come hear about Mirum. First, I just want to mention, I'll be making forward-looking statements, so for a full disclosure of our risk factors, I can refer you to our SEC filings on file with SEC. To give those of you an overview on Mirum who may not be familiar with us, Mirum's founding mission was to create a rare disease company that makes high-impact medicines for patients suffering from rare diseases. Often, we're focused in rare diseases that might be kind of underappreciated by other players in our industry that through focused grit, whether that be development, regulatory, or commercialization, we found that we can unlock a lot of value.

Peter RadovichPresident and COO

Mirum's only been around for eight years, and in eight years, I'm proud to say we have four approved medicines, that you see here on the page, and have grown the top line to be approaching three-quarters of a billion this year, so the guidance of $715 million-$720 million, with excellent growth trends from these four products into 2027, and two new product launches that'll come online primarily in 2028. Really excited about what this focused business model has delivered, both economically as well as for patients. We organize our portfolio into a rare liver business unit and a rare genetic disease business unit.

Peter RadovichPresident and COO

LIVMARLI was the flagship of the company, is our first FDA-approved product in 2021, has two approved indications, just recently had positive phase III data, and a third that I'll tell you more about, that we'll be filing a marketing application for next year. Really excited about that. Also in the rare liver portfolio, both volixibat and brelovitug reported positive pivotal data this year, and heading towards NDA and BLA submissions next year. Really excited about that. In our rare genetic disease business, CTEXLI CHOLBAM, legacy products, but our team has done an excellent job bending the curve with patient finding there, and just recently had ATEBRIOZ approved by the FDA and launched in October. Very excited about the progress we've had across the business. When you look in total, there's over $4 billion in peak sales potential inside of Mirum's portfolio today.

Peter RadovichPresident and COO

$3 billion in the liver portfolio, as well as meaningful opportunity in the rare genetic business. Just a word about our footprint. We have built a commercialization team, sales, marketing, access, medical affairs, supply chain, G&A support across both U.S., Canada, as well as Western and Central Europe, and have distributor and other partners that enable us to expand our reach and our impact on patients living with these diseases around the world. First, LIVMARLI, just to say a bit about LIVMARLI, is really a very strong growth product. Was originally approved in late 2021, September 2021, by FDA in its first indication. Its second indication, PFIC, was approved in 2025, and you can see here on the page, it was an excellent growth trajectory before the second indication came online, but really a nice inflection in 2025, 69% year-on-year growth rate.

Peter RadovichPresident and COO

This trend with the business has really continued into 2026. In fact, the LIVMARLI net product sales for the first three quarters of 2026 have already surpassed 2025. I will tell you more about the drivers of that on the next page here. The Alagille syndrome indication, original FDA approval, as I mentioned, in 2021, EMA and others shortly after that. About 2,000 addressable patients in the U.S. and Europe, about 1,000 in the U.S. LIVMARLI has a commanding market share in this space. North of 80% of patients receiving an IBAT are receiving LIVMARLI, and probably have penetrated about 50% of the addressable population. We still see new patient starts in Alagille syndrome every month, every quarter. Also see weight-based dose adjustments there. That is kind of the core base of the growth of the business.

Peter RadovichPresident and COO

The PFIC opportunity has been the really unique one for those who follow the story. I think you can think about PFIC as almost having two separate entities. One is an infant or pediatric onset version of the disease, the classical PFIC, about 500 addressable patients in the U.S. there, so squarely ultra-rare. LIVMARLI has done very well in that setting, and that is, I think, a pretty well-developed market. What is really new and what is kind of driven the inflection in those revenue growth curves that I showed you is this later onset or adult onset PFIC entity. We had a suspicion and collaborated with KOLs and academics that many of the patients who are in adult liver providers' hands today, who are labeled as unexplained cholestasis or idiopathic cholestasis, that they may in fact have a PFIC gene involved in their disease.

Peter RadovichPresident and COO

This is the effort that the Mirum team has been doing on the patient finding front over the last couple years of kind of going out to adult liver providers, educating them about this literature that some of these patients may in fact have PFIC. We can support genetic testing, which removes that barrier, and ultimately, that has resulted in finding a good number of adult PFIC patients. There are probably about 2,000, we estimate, addressable adult PFIC patients in the United States. Interestingly, I think 10% or less of those are diagnosed today, and that is approximately the penetration here as well. This has been a big part of the growth of the brand, but imagine that we can continue to go much further than 10% in terms of reaching these later onset PFIC patients.

Peter RadovichPresident and COO

As you pivot to the EXPAND study, we recently announced the top line phase III data here. Positive study, really excited about the effects we saw there on pruritus, as well as bile acids. Quite frankly, the results look pretty comparable to the pivotal phase III study in PFIC. So, really excited about those data. Planning on submitting an sNDA in the first half of next year. The study was an interesting design. It enrolled about half the patients had biliary atresia, cholestatic pruritus associated with biliary atresia, and then the other half were essentially a basket study, a long tail of ultra-rare underlying etiologies that lead to the final common pathway of high bile acids, cholestasis, pruritus, fatigue, et cetera. That is the other half.

Peter RadovichPresident and COO

About half the study was biliary atresia, and if you just focus on that half from a market opportunity perspective, biliary atresia pruritus, we believe, can be at least as big as Alagille syndrome. About 1,000 addressable patients in the U.S. You will note that is about the same number of addressable patients as we have in Alagille syndrome. It is a bit higher of a dose, worth mentioning, in biliary atresia, and then no competition in biliary atresia. The competitive program failed here. Excited about adding this to our label. This probably comes online more in 2028, but just exciting continued growth prospects for this brand, 2027, 2028, and beyond. Pivoting to the adult IBAT inhibitor, volixibat, same mechanism of action as LIVMARLI. This product is focused in adult rare cholestatic liver diseases, although you will note from the numbers on the page, more common diseases.

Peter RadovichPresident and COO

Instead of talking about addressable populations of 1,000, 2,000 in the U.S. per indication, here you are talking about 20,000 addressable pruritic PSC patients, 50,000 addressable pruritic PBC patients. Much, much larger opportunities. Obviously, the product will have a different price point than LIVMARLI. We show the clinical data here on this page. The VISTAS data were reported at the EASL meeting in Barcelona earlier this year, the pivotal phase IIb data, really nice effect size, no approved therapies in PSC. Has the potential to be the first approved therapy for this population. In PBC, we have the interim data from VANTAGE shown here, a robust effect size, 2.4 placebo-adjusted delta in pruritus. I think compares very favorably to the landscape of options.

Peter RadovichPresident and COO

It is a busier field from a competitive standpoint, but feel that robust effect size here positions volixibat well to play a role in the PBC space as well. The final pivotal data from the VANTAGE study is expected in the first quarter of next year. An early pivotal data catalyst coming up next year as well. Now pivoting to the other program in our rare liver disease portfolio, brelovitug. This is a program that came in through an acquisition, which is, as I mentioned at the outset, a key part of Mirum's strategy doing business development. Closed the acquisition of Bluejay Therapeutics closer to the beginning of 2026. For those that are not familiar with hepatitis delta, this is a rare viral infection.

Peter RadovichPresident and COO

Depending on the country you are in, between 3%-10% of people who have chronic hepatitis B are also co-infected with delta. Unfortunately, the outcomes for patients with hepatitis delta are quite dire. You will see CME programming from experts saying the D is for deadly. Unfortunately, patients have a much higher risk of portal hypertension, liver decompensation, hepatocellular cancer, and death by literature, probably three times higher risk of those things happening than if you have hep B alone. An unmet need, but a rare disease within a common one. We are really excited both about the market opportunity here as well as the product profile of brelovitug. We reported in the second half of this year positive phase III data from both of the pivotal studies, AZURE-1 and AZURE-4.

Peter RadovichPresident and COO

These were 24-week endpoints focused on the licensing endpoint that FDA wants to see, which is a two-log reduction in viral load and a normalization in liver inflammation as measured by normal ALT levels. This is the regulatory endpoint that is reasonably likely to predict clinical benefit for accelerated approval. So reported those results were positive, and we're heading towards BLA submission. What I'm showing you on the page here is from a presentation at AASLD about a week ago, looking at a cohort of cirrhotic patients who were on brelovitug long term, up to 108 weeks.

Peter RadovichPresident and COO

What you see here, which is, I think, more reflective than the licensing studies that are focused on 24-week endpoints, at 108 weeks, which is reflective of how patients will use this medicine in the real world, is that you can achieve 100% virologic response, nearly three-quarters of patients achieving target not detected. So very robust antiviral efficacy. It doesn't come with a trade-off on ALT. So you can actually get 100% of patients to normalize their ALT values in this cohort. So I think it creates a really unique positioning for the product. Then on the commercial opportunity side, I think these are the kinds of opportunities where Mirum shines. This is an undeveloped market in the U.S. It's interestingly more developed in European countries and other countries because of Hepcludex from Gilead's earlier approval. But in the U.S., completely undeveloped market.

Peter RadovichPresident and COO

About 15,000 patients who are diagnosed, insured, and under care today, but many more than that. We estimate 40,000 prevalence. Others, sponsors think it might be higher. The truth is nobody knows the actual prevalence because there just hasn't been enough testing in the U.S. of people who have hepatitis delta, or sorry, who have hepatitis B for delta. In fact, probably less than 10% of patients have ever had a test for delta. So this is really the wood we have to chop and the work we can do to make a big impact for patients and the kind of economics of this business of finding and diagnosing these hepatitis delta patients. I think the European countries show what's possible.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day